Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024)

Protalix BioTherapeutics (PLX) has 7 years of Short term Debt data on record, last reported at $20.4 million in Q2 2024.

  • For Q2 2024, Short term Debt changed N/A year-over-year to $20.4 million; the TTM value through Jun 2024 reached $20.4 million, changed N/A, while the annual FY2023 figure was $20.3 million, N/A changed from the prior year.
  • Short term Debt reached $20.4 million in Q2 2024 per PLX's latest filing, roughly flat from $20.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $56.4 million in Q2 2021 and bottomed at $3.2 million in Q3 2021.
  • Average Short term Debt over 4 years is $31.3 million, with a median of $20.4 million recorded in 2024.